MBP immunostaining, taken as a measure of the overall extent of myelination, was increased between 9 and 14 months in wild-type controls, but not in APP/PS1 mice, consistent with multiple lines of evidence that myelination is disrupted in AD-like pathology (Desai et al., 2009; Mitew et al., 2010; Shu et al., 2013; Wu et al., 2017; Chao et al., 2018; Dong et al., 2018; Vanzulli et al., 2020). The gene discussed is MBP; the disease is Alzheimer disease.